Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 15/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MELK | Q14680 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5123854 | 0.91 | P2RX7 (0.68) | P2RX7 | |
| SCHEMBL5132359 | 0.87 | P2RX7 (0.54) | P2RX7MCHR1 | |
| SCHEMBL5122915 | 0.86 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL5132277 | 0.85 | P2RX7 (0.51) | P2RX7MCHR1 | |
| SCHEMBL5131429 | 0.85 | P2RX7 (0.56) | P2RX7MCHR1 | |
| SCHEMBL27655378 | 0.84 | P2RX7 (0.65) | P2RX7HRH4MCHR1 | |
| SCHEMBL5126494 | 0.84 | P2RX7 (0.65) | P2RX7HRH4MCHR1 | |
| SCHEMBL5128962 | 0.81 | P2RX7 (0.47) | P2RX7MCHR1 | |
| SCHEMBL27634489 | 0.80 | P2RX7 (0.57) | P2RX7HRH4MCHR1MELK | |
| SCHEMBL5128589 | 0.80 | P2RX7 (0.57) | P2RX7HRH4MCHR1MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | claimed |
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | NQO2, RECQL, CHRM1 | P2RX7 91/4885HRH4 120/4885MCHR1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.